Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own1.60% Shs Outstand50.58M Perf Week4.36%
Market Cap2.58B Forward P/E- EPS next Y-6.62 Insider Trans-8.02% Shs Float47.32M Perf Month-17.76%
Income-121.00M PEG- EPS next Q-1.81 Inst Own99.31% Short Float9.24% Perf Quarter-37.54%
Sales37.60M P/S68.59 EPS this Y12.20% Inst Trans1.72% Short Ratio7.73 Perf Half Y-21.91%
Book/sh13.17 P/B3.87 EPS next Y-64.30% ROA-26.60% Target Price70.53 Perf Year6.58%
Cash/sh9.95 P/C5.13 EPS next 5Y17.20% ROE-31.00% 52W Range41.67 - 90.98 Perf YTD9.94%
Dividend- P/FCF- EPS past 5Y-52.00% ROI-63.20% 52W High-40.68% Beta2.32
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin98.30% 52W Low29.52% ATR4.13
Employees520 Current Ratio8.50 Sales Q/Q5840.90% Oper. Margin- RSI (14)43.30 Volatility7.91% 8.14%
OptionableYes Debt/Eq0.00 EPS Q/Q7.00% Profit Margin- Rel Volume0.94 Prev Close50.99
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume565.38K Price53.97
Recom1.90 SMA204.10% SMA50-18.44% SMA200-18.58% Volume156,615 Change5.85%
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
May-11-18Upgrade Barclays Equal Weight → Overweight $62 → $74
May-10-18Initiated Goldman Neutral $63
Apr-18-18Upgrade SunTrust Hold → Buy
Mar-22-18Resumed Piper Jaffray Overweight $67
Feb-21-18Reiterated Stifel Buy $85 → $74
Jan-22-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Initiated Credit Suisse Outperform $67
Dec-05-17Reiterated Barclays Equal Weight $60 → $62
Dec-04-17Upgrade Jefferies Hold → Buy
Sep-14-17Upgrade Wedbush Neutral → Outperform $62
Aug-23-17Downgrade SunTrust Buy → Hold $55
Aug-17-17Initiated Evercore ISI In-line $63
Aug-08-17Reiterated H.C. Wainwright Neutral $72 → $75
Apr-19-17Downgrade Wedbush Outperform → Neutral $80 → $75
Apr-19-17Downgrade H.C. Wainwright Buy → Neutral $88 → $72
Apr-06-17Downgrade Jefferies Buy → Hold
Mar-23-17Downgrade Piper Jaffray Overweight → Neutral
Nov-21-18 01:52AM  Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT Thomson Reuters StreetEvents +5.85%
Nov-14-18 08:30AM  Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019 GlobeNewswire
Nov-09-18 08:30AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
07:35AM  Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-06-18 04:31PM  Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3 Zacks
12:30AM  Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending Insider Monkey
Nov-05-18 05:20PM  Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  Ultragenyx: 3Q Earnings Snapshot Associated Press
04:05PM  Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Nov-02-18 11:41AM  Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO Zacks
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 08:30AM  Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Oct-26-18 08:00AM  Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders GlobeNewswire -18.09%
Oct-22-18 07:00AM  Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder) GlobeNewswire
Oct-18-18 08:30AM  Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Oct-03-18 07:50AM  Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-28-18 10:58AM  Ultragenyx Reports Top-line Data From Gene Therapy Candidate Zacks
Sep-27-18 07:00AM  Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose GlobeNewswire -6.88%
Sep-26-18 08:30AM  Ultragenyx to Present at Jefferies Gene Therapy Summit GlobeNewswire
Sep-25-18 08:00AM  Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen ACCESSWIRE
Sep-20-18 03:49PM  Ultragenyx's Shares Surge More Than 80% in the Year So Far Zacks
Sep-17-18 08:30AM  Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer GlobeNewswire
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Aug-30-18 09:50AM  Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data Zacks
Aug-29-18 08:30AM  Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders GlobeNewswire +6.68%
Aug-28-18 05:45PM  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval Zacks
Aug-27-18 04:01PM  Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Aug-23-18 01:55PM  Edited Transcript of RARE earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents -7.48%
Aug-03-18 05:38PM  Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2 Zacks -9.77%
Aug-02-18 08:50PM  Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:46PM  Ultragenyx: 2Q Earnings Snapshot Associated Press
04:05PM  Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-27-18 08:30AM  Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
08:30AM  Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program GlobeNewswire
Jul-25-18 07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-20-18 06:00AM  5 Favorite Biotech Bets Investopedia
Jun-29-18 09:00AM  Ultragenyx Announces Positive CHMP Opinion for Mepsevii (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII GlobeNewswire
Jun-19-18 07:30AM  Report: Developing Opportunities within Spartan Motors, Ultragenyx Pharmaceutical, Advanced Energy Industries, Verisk Analytics, Cogent Communications, and ADTRAN Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-14-18 12:33PM  Why Biotech Stocks May Reach New Highs Investopedia
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 04:05PM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
May-29-18 08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and BioMarin Pharmaceutical ACCESSWIRE
May-24-18 08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 05:01PM  Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine GlobeNewswire
May-17-18 08:30AM  Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH) GlobeNewswire
May-10-18 03:46AM  Edited Transcript of RARE earnings conference call or presentation 7-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-07-18 04:26PM  Ultragenyx: 1Q Earnings Snapshot Associated Press +6.35%
04:05PM  Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
12:30PM  Ultragenyx Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
May-01-18 08:30AM  Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Apr-30-18 08:30AM  Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of Xlinked Hypophosphatemia (XLH) in Children and Adults GlobeNewswire
Apr-25-18 08:10AM  Investor Expectations to Drive Momentum within MicroStrategy, Marcus & Millichap, Gentex, Ultragenyx Pharmaceutical, Dave & Buster's Entertainment, and Glatfelter Discovering Underlying Factors of Influence GlobeNewswire
Apr-23-18 08:30AM  Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia GlobeNewswire
Apr-18-18 02:19PM  Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets TheStreet.com
11:14AM  2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities American City Business Journals
Apr-17-18 03:19PM  Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH) PR Newswire
01:25PM  Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with XLinked Hypophosphatemia (XLH) GlobeNewswire
01:04PM  FDA approves Ultragenyx's treatment for rare type of rickets Reuters
Apr-16-18 06:10PM  North Bay company looks for 2nd rare-disease drug approval, voucher in 5 months American City Business Journals
Mar-08-18 08:00AM  Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Mar-07-18 08:40AM  Ultragenyx says three patients in phase 1/2 gene therapy study had positive results MarketWatch
08:00AM  Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Mar-03-18 08:11PM  Edited Transcript of RARE earnings conference call or presentation 20-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and CRISPR Therapeutics ACCESSWIRE
Feb-23-18 08:00AM  Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of XLinked Hypophosphatemia in Children GlobeNewswire
08:00AM  Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children PR Newswire
Feb-20-18 05:17PM  Ultragenyx reports 4Q loss Associated Press
04:05PM  Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update GlobeNewswire
12:30PM  Ultragenyx Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
Feb-16-18 08:15AM  Recent Analysis Shows Continental Building Products, Ultragenyx Pharmaceutical, Hilltop, The Blackstone Group, Century Aluminum, and Physicians Realty Trust Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-14-18 04:05PM  Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 Financial Results and Corporate Update GlobeNewswire +6.67%
06:19AM  Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): Does The -26.93% Earnings Decline Make It An Underperformer? Simply Wall St.
Feb-08-18 08:30AM  Ultragenyx to Present at Leerink Partners Global Healthcare Conference GlobeNewswire -5.78%
Jan-29-18 08:30AM  Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President GlobeNewswire
Jan-24-18 11:02AM  Top NasdaqGS High Growth Stock Simply Wall St.
08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences Corporation and Ultragenyx Pharmaceutical ACCESSWIRE
Jan-23-18 09:40PM  Ultragenyx Announces Pricing of Public Offering of Common Stock GlobeNewswire +8.90%
Jan-22-18 04:15PM  Ultragenyx Announces Proposed Public Offering of Common Stock GlobeNewswire +8.60%
Jan-09-18 08:07AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks -5.06%
02:07PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE Business Wire
Jan-07-18 11:00AM  Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Jan-04-18 09:08AM  Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients GlobeNewswire
08:35AM  Ultragenyx to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 08:02AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit +6.27%
Dec-29-17 01:03PM  Ultragenyx Pharmaceutical, Inc. Value Analysis (NASDAQ:RARE) : December 29, 2017 Capital Cube
Dec-28-17 07:40AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 28, 2017 Capital Cube
Dec-18-17 08:55AM  Ultragenyx sells rare drug voucher for $130 mln to Novartis MarketWatch
08:30AM  Ultragenyx Sells Priority Review Voucher for $130 million GlobeNewswire
Dec-15-17 08:30AM  Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children PR Newswire
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Dec-04-17 04:06PM  Does This Rare-Disease Biotech Have A Winner On Its Hands? Investor's Business Daily
09:29AM  Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers TheStreet.com
07:53AM  Ultragenyx shares rise 4% on late-stage results for rare disease therapy MarketWatch
07:30AM  Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia GlobeNewswire
Dec-01-17 07:13AM  Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : December 1, 2017 Capital Cube
Nov-30-17 08:30AM  Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4 GlobeNewswire +5.72%
08:04AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Nov-27-17 08:03AM  See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc. Markit
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aliski WilliamDirectorNov 08Sale55.676,000334,02096,350Nov 08 06:47 PM
Sharp ShaliniCFO & Executive Vice PresidentOct 31Option Exercise0.8212,0009,78062,128Oct 31 06:17 PM
Aliski WilliamDirectorOct 08Sale73.386,000440,280102,350Oct 09 04:36 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 25Option Exercise0.823,3502,73056,828Sep 27 04:07 PM
Sharp ShaliniCFO & Executive Vice PresidentSep 25Sale90.076,700603,46950,128Sep 27 04:07 PM
Parschauer Karah HerdmanEVP and General CounselAug 21Sale78.535,000392,6509,181Aug 21 06:59 PM
Aliski WilliamDirectorAug 08Sale76.663,750287,47572,610Aug 08 05:32 PM
Parschauer Karah HerdmanEVP and General CounselJun 21Sale82.771,226101,47614,181Jun 21 05:32 PM
Huizenga Theodore AlanVP, Controller and PAOJun 15Option Exercise21.002,95562,05512,895Jun 15 07:55 PM
Huizenga Theodore AlanVP, Controller and PAOJun 15Sale83.7095579,93411,940Jun 15 07:55 PM
Huizenga Theodore AlanVP, Controller and PAOJun 13Sale76.971,338102,9869,940Jun 13 06:41 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 07Option Exercise0.823,3502,73060,178Jun 07 07:17 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 07Sale80.076,700536,45653,478Jun 07 07:17 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 30Option Exercise0.826,5005,29870,174May 30 07:29 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 30Sale70.1713,000912,17157,174May 30 07:29 PM
Fust Matthew KDirectorMay 30Sale72.006,319454,9698,750May 30 07:26 PM
Parschauer Karah HerdmanEVP and General CounselMay 10Sale60.001,46587,90016,056May 10 05:07 PM
Aliski WilliamDirectorApr 19Sale53.9765035,081108,350Oct 09 04:36 PM
Aliski WilliamDirectorJan 23Option Exercise21.0011,500241,50073,360Jan 25 05:07 PM